Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
GEA Group Aktiengesellschaft (ETR:G1A) outlined its 2030 growth and profitability targets during an Industrial Technology Conference presentation, with Investor Relations Manager Eduard Biller saying the industrial equipment supplier aims to lift revenue above EUR 7 billion and raise its EBITDA marg
The global GLP-1 Receptor Agonist Market was valued at USD 66.4 billion in 2025 and is projected to grow from USD 82.0 billion in 2026 to USD 185.3 billion
Zoetis has gotten torched over the last six months - since December 2025, its stock price has dropped 36.6% to $78.46 per share. This was partly driven by it...
Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.
Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted. The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehensive internal and external search. Dave and Cecile will work together to ensure a seamless transition.
June 17, 2026 -- The award recognizes distinguished attorneys and public-interest advocates whose careers have advanced consumer protection, challenged corporate misconduct, and improved public safety.
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innova...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav...
GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.
